(Q39660556)

1 July 2019

title

Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A. (English)

1 reference

1 July 2019

0 references

6

Giuseppe Giaccone

1 reference

1 July 2019

Patricia Steeg

5

object named as

Patricia S Steeg

1 reference

1 July 2019

author name string

Min Chen

1

1 reference

1 July 2019

Donna Voeller

2

1 reference

1 July 2019

Victor E Marquez

3

1 reference

1 July 2019

Frederic J Kaye

4

1 reference

1 July 2019

Maria Zajac-Kaye

7

1 reference

1 July 2019

publication date

1 October 2010

1 reference

1 July 2019

International Journal of Oncology

published in

1 reference

1 July 2019

volume

37

1 reference

1 July 2019

issue

4

1 reference

1 July 2019

page(s)

963-971

1 reference

1 July 2019

Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation

cites work

1 reference

12 December 2020

Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression

1 reference

12 December 2020

Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications

1 reference

12 December 2020

Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma

1 reference

12 December 2020

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

1 reference

12 December 2020

DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.

1 reference

12 December 2020

Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer

1 reference

12 December 2020

Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells

1 reference

12 December 2020

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms

1 reference

12 December 2020

Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228

1 reference

12 December 2020

Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells

1 reference

12 December 2020

Inhibition of DNA methylation and reactivation of silenced genes by zebularine

1 reference

12 December 2020

Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase

1 reference

12 December 2020

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

1 reference

12 December 2020

Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells

1 reference

12 December 2020

Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme

1 reference

12 December 2020

Preferential response of cancer cells to zebularine.

1 reference

12 December 2020

Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells.

1 reference

12 December 2020

Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine

1 reference

12 December 2020

The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma

1 reference

12 December 2020

Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.

1 reference

12 December 2020

DNA methylation and gene silencing in cancer

1 reference

12 December 2020

Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy

1 reference

12 December 2020

Epigenetic therapy of cancer: past, present and future

1 reference

12 December 2020

Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura

1 reference

12 December 2020

Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression.

1 reference

12 December 2020

The epigenomics of cancer

1 reference

12 December 2020

Histone deacetylase inhibitors in combinations: will the preclinical promises be kept?

1 reference

12 December 2020

Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells

1 reference

12 December 2020

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes

1 reference

12 December 2020

Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter.

1 reference

12 December 2020

Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.

1 reference

12 December 2020

Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice.

1 reference

12 December 2020

Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia

1 reference

12 December 2020

Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase

1 reference

12 December 2020

Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine

1 reference

12 December 2020

Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation

1 reference

12 December 2020

CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine.

1 reference

12 December 2020

The N-terminal domain of c-Myc associates with alpha-tubulin and microtubules in vivo and in vitro

1 reference

12 December 2020

Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB

1 reference

12 December 2020

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

1 reference

12 December 2020

Kinetics of phosphorylation of 5-aza-2′-deoxycytidine by deoxycytidine kinase

1 reference

12 December 2020

A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems.

1 reference

12 December 2020

Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma

1 reference

12 December 2020

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

1 reference

12 December 2020

Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone 1 1Edited by J. Karn

1 reference

12 December 2020

Identifiers

DOI

10.3892/IJO_00000747

1 reference

1 July 2019

PMCID

6545580

1 reference

1 July 2019

PubMed ID

20811718

1 reference

1 July 2019